That may be so, but it is a highly expensive learning process, with the greatest burden of cost being borne by industry players like Danone, the company’s vice president of research and development in its dairy division, Frederic René, said after EFSA’s gut/immune function meeting in Amsterdam last week.
With Danone having twice submitted and then withdrawn dossiers for its probiotic yoghurts Actimel and Activia, citing a lack of clarity from EFSA at the time of both withdrawals, René said EFSA needed to be more communicative with applicants.
He said it was not acceptable that EFSA undertook its learning process by analysing dossiers and publishing opinions on them.
“It’s a trial and error process and I don’t think it is the right way to make a learning process.”
Like several others at the meeting, he proposed pre-screening of dossiers by EFSA’s Dietetic Products, Nutrition and Allergies (NDA) panel, a proposal NDA chief, Professor Albert Flynn, said was unlikely due to a lack of resources.
Lack of depth and precision
René said he was disappointed by the lack of specific guidance forthcoming at the meeting, save for some advice on clinical outcomes.
“In fact there is nothing really new,” he said. “We need to be more precise and maybe go in depth as proposed by many of the people attending the meeting.”
He said the situation remained unclear as to when health claim submissions for Activia and Actimel may be formally submitted to the process for a third time.